DNB Asset Management AS Trims Position in Tempus AI, Inc. $TEM

DNB Asset Management AS trimmed its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 30.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 35,637 shares of the company’s stock after selling 15,515 shares during the period. DNB Asset Management AS’s holdings in Tempus AI were worth $2,104,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in TEM. GC Wealth Management RIA LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $399,267,000. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after buying an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after buying an additional 965,730 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Tempus AI in the second quarter valued at about $54,020,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Trading Up 0.8%

Shares of Tempus AI stock opened at $45.88 on Thursday. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company’s 50-day simple moving average is $49.11 and its 200-day simple moving average is $59.69. The firm has a market cap of $8.24 billion, a price-to-earnings ratio of -26.67 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the previous year, the business posted ($0.24) earnings per share. The business’s revenue was up 36.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Insider Transactions at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total transaction of $8,500,362.50. Following the transaction, the chief executive officer directly owned 8,841,783 shares in the company, valued at $452,080,364.79. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares in the company, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 343,449 shares of company stock worth $16,871,372. Company insiders own 24.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TEM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a report on Wednesday, February 25th. Mizuho started coverage on shares of Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. BTIG Research dropped their price target on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Morgan Stanley dropped their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.64.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.